RATIONALE: Previous studies have found DNA methylation (DNAm) is associated with body mass index (BMI). However, it is unknown whether pre-adolescence DNAm is associated with BMI status changes over adolescence period. METHODS: In total, 323 (n 5 185 males) children from a birth cohort established on the Isle of Wight (IoW), UK, were included in the study. Random forest was applied to screen CpGs potentially associated with BMI at ages 10 and 18 years for each gender. BMI status transitions rom pre-to post-adolescence were defined based on BMI z-scores. Multinomial regression model was used to assess the association of BMI status change with DNAm at age 10 years at CpGs that passed screening. To evaluate gender specificity, interaction between DNAm and gender was included in the model. Adjusting factors include gender, age of puberty onset, smoking status and maternal BMI. A p-value <0.05 after correcting for multiple testing by controlling FDR 5 0.05 indicates statistical significance. RESULTS: Top 100 CpGs after screening were analyzed in 323 children where both BMI and DNAm were available at ages 10 and 18 years. We identified 3 CpGs associated with BMI status change regardless of gender. In IoW, DNAm at cg23664926 was associated with a positive decrease in BMI (from overweight to normal) (log-OR 5 2.36, p<SUB>FDR</SUB> 5 0.031), while at cg03182908 (log-OR 5 2.82, p<SUB>FDR</SUB> 5 0.031) and cg07355346 (log-OR 5 4.07, p<SUB>FDR</SUB> 5 0.031), DNAm was associated with persistent overweight BMI status. CONCLUSIONS: Pre-adolescence DNAm has a potential to predict future BMI status changes during adolescence. . This meta-analysis systematically evaluated the efficacy of pharmacotherapy and AIT versus placebo on nasal symptoms associated with PAR. METHODS: The meta-analysis protocol is registered in PROSPERO [CRD42018105632] per PRISMA guidelines. Randomized, double-blind, placebo-controlled trials evaluating the efficacy of FDA-approved pharmacotherapies or sublingual immunotherapy tablets (SLIT-tablets), and commercially-available or standardized subcutaneous immunotherapy (SCIT) products for adult PAR were identified from systematic searches of PubMED/EMBASE through 5/18/2018. Nasal provocation, environmental exposure unit, or cross-over trials were excluded. The primary outcome was mean difference in total nasal symptom score (TNSS; max 5 12) between active treatment and placebo at the end of the primary assessment period. Random-effect meta-analyses estimated the mean difference for each drug group weighted by inverse of trial variance. RESULTS: There was considerable heterogeneity among trials in disease severity, trial duration, and rescue medication use (allowed in AIT active and placebo groups, not allowed in most pharmacotherapy trials). Mean difference in TNSS versus placebo (95% CI) for INCS was 0.82 (0.66, 0.97; 14 trials), for oral antihistamine was 0.27 (0.11, 0.42; 3 trials), for SCIT was 1.13 (0.65, 1.61; 4 trials), and for SLIT-tablets was 0.65 (0.42, 0.88; 3 trials). In the 1 eligible trial for montelukast, mean difference versus placebo was 0.32 (0.14, 0.50). CONCLUSIONS: All treatments significantly improved TNSS for adult PAR versus placebo, although 95% CI were overlapping. Head-to-head trials are needed for definitive comparisons because of methodological differences between AIT and pharmacotherapy trials. AstraZeneca, Gaithersburg, MD. RATIONALE: Approximately 5-10% of patients with asthma have severe asthma (SA), which necessitates subspecialist care and intensive therapy. Few data are available regarding the contemporary real-world characteristics of United States adults with SA. METHODS: CHRONICLE (NCT03373045) is an ongoing observational study of patients with SA treated by US allergists/immunologists or pulmonologists. Eligible patients are adults receiving biologic therapy and/ or long-term systemic corticosteroids (SCS), as well as those uncontrolled (per ATS/ERS) on high-dosage inhaled corticosteroids (HD ICS) and additional controllers. Patient characteristics at screening/enrollment were summarized for all eligible and enrolled patients as of 9/15/18. RESULTS: Between 2/27/18 and 9/15/18, 65 sites evaluated 810 eligible patients with SA: 60% were receiving biologic therapy, 8% long-term SCS, and 38% HD ICS without biologics or long-term SCS. Of 517 patients enrolled, 426 had complete data: 70% female; mean age at enrollment, 55 years (range: 18-83); mean BMI (kg/m 2 ), 33 (17-64); and 3%/29% current/ former smokers, respectively. The most prevalent diagnosed comorbidities influencing asthma control were allergic rhinitis (40%), confirmed seasonal aeroallergen allergy (18%), confirmed perennial aeroallergen allergy (18%), and gastroesophageal reflux disease (10%). At least 1 exacerbation in the past 12 months was reported by 62% (mean 1.9 exacerbations). CONCLUSIONS: CHRONICLE provides a detailed, real-world, contemporary description of adults with SA treated by United States subspecialists. One-third of patients with SA were current/former smokers, a population commonly excluded from interventional trials. Despite specialty assessment and treatment, >60% of patients with SA experienced exacerbations within the past year.
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